Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer - Wikidata - awgldk - TriplyDB

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

http://www.wikidata.org/entity/Q36785930

about

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer Recurrent rearrangements in prostate cancer: causes and therapeutic potential Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines The ETS family of oncogenic transcription factors in solid tumours.Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Prostate cancer genomics: towards a new understanding Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement Urine markers in monitoring for prostate cancer.Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians Horizon scanning for novel therapeutics for the treatment of prostate cancer.The complexity of prostate cancer: genomic alterations and heterogeneity.Transcriptional network of androgen receptor in prostate cancer progression.Recurrent gene fusions in prostate cancer: their clinical implications and uses.The genomic landscape of prostate cancer FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.Drug discovery in advanced prostate cancer: translating biology into therapy.ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.Poly-gene fusion transcripts and chromothripsis in prostate cancer.High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR.Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.ETS gene fusions and prostate cancer.ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells.Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.Increased transcriptional and metabolic capacity for lipid metabolism in the peripheral zone of the prostate may underpin its increased susceptibility to cancer.Genomic predictors of prostate cancer therapy outcomes.High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

P2860

Q24603649-6AC548ED-CA64-4D6F-8C48-8AB8F1EAB40C Q24606772-FBBE9243-FD31-4E33-90CF-9C6535CB4F5F Q24647034-BE832876-1742-4451-9EC9-F0F0C225B53C Q26851525-9DA359F9-161C-419F-BD5E-3C4DD2DB74EC Q26997884-05B46A23-0C5B-492B-A013-F1959A68092C Q33507490-1E8F50DA-73C6-4194-8821-FE3CD867220E Q33698635-70EC8479-23CF-4A0E-814D-D3436DE41ABB Q33723651-F7F2B228-AE7E-4D16-B4FE-57364BE94C9F Q33760590-7CC3ECE5-4529-4586-85EA-02893616E28C Q33813603-B5657590-7B64-412A-AAC4-C01B2B5D403D Q33988757-51DF247F-E1FE-47B3-B35B-F7924FCD1A29 Q34555986-FBF0E6EC-4B5F-4D68-9C39-8AA8F2283AC2 Q35741647-A1152BE8-3E77-4869-8386-EC88D21D4508 Q36388955-E547841A-5590-4EA4-A562-FA8452E09D49 Q36901964-31BF17D1-4751-40CD-88E7-9877DC4681A0 Q37292004-6C2BBFEB-539B-4C2E-95A6-08E3B59443D9 Q37383459-0FC1FB3D-281C-4BB4-8FEF-838AB0AA7469 Q37400523-67091C2D-9DA5-4AFE-8425-CF9426487E08 Q37571461-D508744F-537A-4567-A3B7-E5E1954ACD6F Q37702713-0E644094-1892-4977-BF4F-60ECCE55AEA5 Q37792060-78C9CBEA-8D50-4B95-9EB2-F01D3A4864B5 Q38058243-16BFBCB7-C083-4058-B5A9-FD85ABF3D7B2 Q38100269-70F20AB6-B135-492F-BFBF-2ADFE59A966D Q38102618-55CC9176-6696-42AE-881C-E8E7E105AEA3 Q38109474-51927B2C-DFCA-4F36-B4DC-4890B5F3DA77 Q38330339-CCF1F4E2-D65B-4DEC-9691-48E5CBAB62D2 Q38839110-C241794D-5A43-4E5B-AB48-711BBCBCE89A Q39178242-5141291C-3142-4F25-8A32-8E81560F0CA5 Q39289831-846734E2-5A20-4976-A50E-8691EC0BB7EE Q39496666-2A2FF9BB-BF4B-40DD-8FD1-C6813EAA3465 Q40118714-02B1F57C-F970-43D4-BA7C-B3B58E30FD28 Q40322483-34847EE0-100D-47B4-B3A0-CC14DC502E33 Q42064904-4A9A008F-1D05-41B8-B91B-B0362AD647A2 Q42288618-428D3156-A0BA-4149-89CD-5156079B231B Q42494288-CD5F5109-86BC-452C-A0C3-08961295ED96 Q43119456-C78EF5F1-7733-4A97-8165-8AFE618CA41E Q44664369-15BC6F12-A1B2-484B-AE62-34C31A521350 Q44958045-16D76A4A-53AF-4683-B509-4998D62283CF Q51074214-778A2959-57D4-464B-A0BC-702B4909F9C6 Q52623792-B10BC8E9-AA7C-4B24-96DA-AED600E6BE2D

P2860

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

http://www.wikidata.org/entity/Q36785930

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

@en

type

label

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

@en

prefLabel

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

@en

P1433

Q36785930-62F9915F-0417-4403-9A1E-1E37C375CEAA

P1476

Q36785930-9D5ED3E7-6269-4ED4-AB11-223195215219

P2093

Q36785930-0204868C-6920-4B8A-9719-6C219E4753A0

Q36785930-09B75561-02C9-40D1-BC75-50AA3F2C5E15

Q36785930-09CB3E86-89D8-48BE-8A0C-651CB612B152

Q36785930-0FA17F72-CA0A-4879-B8D0-B4AC953D20B9

Q36785930-44E7AE0B-4CEC-43A8-8350-9A81384176FD

Q36785930-4F69ED9D-7FCC-4B46-84D4-A125A9002002

Q36785930-603667C2-D957-4A3B-BF62-231BE4286AB4

Q36785930-63017686-11C1-4BD9-9917-77D109A0DE53

Q36785930-7F23A245-2ACB-4920-ACE2-DBCEF4819C4C

Q36785930-8DD0B619-1406-4B2A-902D-54FEB8FB1E03

P2860

Q36785930-0B4E767A-0F69-4B29-803E-48A1FBBC549C

Q36785930-17016E7E-2B74-4D33-90A0-D5E757F01F97

Q36785930-1A1240F2-1B4C-4C72-B945-D4BFC704A71A

Q36785930-3E1DF049-A15E-427C-BCC1-177D67705C98

Q36785930-40BAD977-EF70-4F3D-AE74-DCBA01C9076D

Q36785930-411D3AE4-2A02-4319-8D00-F975B2867ED3

Q36785930-41F03C9E-C48F-4F78-8D25-7595E97A56DF

Q36785930-586AF028-FAB1-4F68-8282-5A9FD66A3165

Q36785930-5C065D7F-016D-4412-A158-E954E6BFB919

Q36785930-65BC3400-FE6A-4037-9F1D-823C08D09E88

P2888

Q36785930-5EF7F773-18B1-4F5D-B6AA-5058FE8AE6A7

P304

Q36785930-495B156D-A73C-47C2-A498-36078B8C37D2

P31

Q36785930-5CF1833B-1A1E-4F34-8578-15B0E8D24A06

P356

Q36785930-98A1430D-FF58-4733-A666-F061272C89B6

P407

Q36785930-45B70BC6-67DE-49CE-AEE6-91C877CF732D

P433

Q36785930-70956899-4750-4968-8AEC-DDD2D22A703B

P478

Q36785930-4B41B0BA-5E1A-4CED-B9D6-657FF2788A40

P50

Q36785930-FCB3FE3A-ACC5-4D0B-9A6B-B6A61DBB6FD9

P577

Q36785930-9880832E-530D-4942-BCB1-7F66ABF7F47D

P5875

Q36785930-0CDEC149-3444-4C40-82D4-1BBCA67AC141

P6179

Q36785930-7205A6B7-8F56-4DDC-B404-20F98D4B2EB6

P698

Q36785930-3AC4643A-E159-4E54-8F7A-DBD7E311B09A

P932

Q36785930-58C620CE-371C-4D8F-87DB-1691A7907DEC

P356

P1433

British Journal of Cancer

P1476

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

@en

P2093

A Fletcher

http://www.w3.org/2001/XMLSchema#string

A Reid

http://www.w3.org/2001/XMLSchema#string

C E Massie

http://www.w3.org/2001/XMLSchema#string

C Foster

http://www.w3.org/2001/XMLSchema#string

C S Cooper

http://www.w3.org/2001/XMLSchema#string

G Attard

http://www.w3.org/2001/XMLSchema#string

G Fisher

http://www.w3.org/2001/XMLSchema#string

G Kovacs

http://www.w3.org/2001/XMLSchema#string

I G Mills

http://www.w3.org/2001/XMLSchema#string

J Clark

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Cell- and gene-specific regulation of primary target genes by the androgen receptor.

Pathology of benign prostatic hyperplasia.

Cellular and molecular pathology of prostate cancer precursors.

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation.

Long-term outcome among men with conservatively treated localised prostate cancer.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

P2888

P304

314-320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604472

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232774992

http://www.w3.org/2001/XMLSchema#string

P6179

1033073257

http://www.w3.org/2001/XMLSchema#string

P698

18594527

http://www.w3.org/2001/XMLSchema#string

P932

2480965

http://www.w3.org/2001/XMLSchema#string